ReviewFrontiers in medicine2020
Long Non-coding RNAs in Cancer: Implications for Diagnosis, Prognosis, and Therapy.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Long Non-Coding RNAs as Diagnostic Biomarkers for Ischemic Stroke: A Systematic Review and Meta-Analysis.Genes · 2024Pooled it
- LncRNA MALAT1 as diagnostic and prognostic biomarker in colorectal cancers: A systematic review and meta-analysis.PloS one · 2024Pooled it
- The Prognostic Value of lncRNA MCM3AP-AS1 on Clinical Outcomes in Various Cancers: A Meta- and Bioinformatics Analysis.Disease markers · 2022Pooled it
- Clinicopathological and Prognostic Significance of Long Non-coding RNA MIAT in Human Cancers: A Review and Meta-Analysis.Frontiers in genetics · 2021Pooled it
- Therapeutic resistance in cancer: lncRNAs as modulators and targets for cancer therapy.Genes & diseases · 2026Review
- The Role of Long Noncoding RNAs in Modulation of Stress Granules in Cancer.Journal of cellular and molecular medicine · 2026Review
- Inverse GAS5-SFXN1 Correlation in Triple-Negative Breast Cancer: Insights from Bioinformatics and Tissue Expression Analysis.Iranian biomedical journal · 2026Article
- Long Non-Coding RNA Expression in B-Cell Precursor Acute Lymphoblastic Leukemia: Analysis of LINC-PINT, MEG3, BALR6, and ZEB1-AS1.Life (Basel, Switzerland) · 2026Article
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- The TMPO-AS1/hsa-let-7b-5p regulatory axis shapes transcriptional heterogeneity and immune landscape in lung adenocarcinoma.Cell division · 2026Article
- Long non-coding RNAs in B-cell acute lymphoblastic leukemia: Disease implication, challenges and therapeutic opportunities.Non-coding RNA research · 2026Review
- The expression profiling of serum circPHLPP2 and LncRNA ILF3 in colorectal cancer patients.Scientific reports · 2026Article
- Hypoxia Signaling and Non-Coding RNAs: Regulatory Networks and Therapeutic Implications in Breast Cancer.Current issues in molecular biology · 2026Review
- Diagnostic and prognostic values of differentially expressed genes in canine mammary carcinoma: An integrated bioinformatics analysis.PloS one · 2026Article
- Upregulation of the HOXA10-AS1 LncRNA in Gastric Cancer: An Expression and Bioinformatics Analysis.Iranian journal of pathology · 2026Article
- Metformin Inhibits the Growth of Hypopharyngeal Squamous Cell Carcinoma of Fadu Cell and Down-Regulates LncAROD to Improve Prognosis.Anti-cancer agents in medicinal chemistry · 2026Article
- Regulation Ratio: A Singular Multi-Omic Measurement of Gene Regulatory Mechanisms.Computational and structural biotechnology journal · 2026Article
- Expression of MIR155HG, LOC283856, KIAA0125, and LOC100190986 as potential prognostic and predictive biomarkers for breast cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
- Silencing TMEM105 suppresses gastric cancer cell growth and migration via proliferation-associated pathways.BMC cancer · 2025Article
- Article
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) are major components of cellular transcripts that are arising as important players in various biological pathways. They have received extensive attention in recent years, regarded to be involved in both developmental processes and various diseases. Due to their specific expression and functional diversity in a variety of cancers, lncRNAs have promising applications in cancer diagnosis, prognosis and therapy. Studies have shown that lncRNAs with high specificity and accuracy have the potential to become biomarkers in cancers. LncRNAs can be noninvasively extracted from body fluids, tissues and cells, and can be used as independent or auxiliary biomarkers to improve the accuracy of diagnosis or prognosis. Currently, the most well-recognized lncRNA is PCA3, which has been approved for use in the diagnosis of prostate cancer. Moreover, the underlying mechanisms of lncRNAs were explored as therapeutic targets, which have been investigated in clinical trials of several cancers. In this review, we presented a compilation of recent publications, clinical trials and patents, addressing the potential of lncRNAs that could be considered as biomarkers or therapeutic targets, with the hopes of providing promised implications for future cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.